Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Filippo de Marinis"'
Autor:
Dae Ho Lee, Ming-Sound Tsao, Karl-Otto Kambartel, Hiroshi Isobe, Ming-Shyan Huang, Carlos H Barrios, Adnan Khattak, Filippo de Marinis, Smita Kothari, Ashwini Arunachalam, Xiting Cao, Thomas Burke, Amparo Valladares, Javier de Castro
Publikováno v:
PLoS ONE, Vol 13, Iss 8, p e0202865 (2018)
BACKGROUND:The goals of this multinational retrospective study were to describe treatment patterns and survival outcomes by receipt of molecular testing and molecular status of patients with advanced non-small cell lung cancer (NSCLC). METHODS:This c
Externí odkaz:
https://doaj.org/article/f890e926ac6d45e7b25173348942f17d
Autor:
Jessica Davies, Manali Patel, Cesare Gridelli, Filippo de Marinis, Daniel Waterkamp, Margaret E McCusker
Publikováno v:
PLoS ONE, Vol 12, Iss 4, p e0175679 (2017)
Most patients with advanced non-small cell lung cancer (NSCLC) have a poor prognosis and receive limited benefit from conventional treatments, especially in later lines of therapy. In recent years, several novel therapies have been approved for secon
Externí odkaz:
https://doaj.org/article/87769d179ebe4785ad3caf762b22b082
Autor:
Filippo de Marinis, Amparo Valladares, Dae Ho Lee, Smita Kothari, Adnan Khattak, Javier de Castro, Ming Shyan Huang, Ming-Sound Tsao, Hiroshi Isobe, Ashwini Arunachalam, Xiting Cao, Carlos Barrios, Karl Otto Kambartel, Thomas Burke
Publikováno v:
PLoS ONE, Vol 13, Iss 8, p e0202865 (2018)
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Background The goals of this multinational retrospective study were to describe treatment patterns and survival outcomes by receipt of molecular testing and molecular status of patients with advanced non-small cell lung cancer (NSCLC). Methods This c
Autor:
Cesare Gridelli, Daniel Waterkamp, Filippo de Marinis, Manali I. Patel, Margaret Elizabeth McCusker, Jessica Davies
Publikováno v:
PLoS ONE
PLoS ONE, Vol 12, Iss 4, p e0175679 (2017)
PLoS ONE, Vol 12, Iss 4, p e0175679 (2017)
Most patients with advanced non-small cell lung cancer (NSCLC) have a poor prognosis and receive limited benefit from conventional treatments, especially in later lines of therapy. In recent years, several novel therapies have been approved for secon